Jacobio Pharmaceuticals (HKG:1167) received approval from China's National Medical Products Administration for glecirasib to be launched on the market, a Thursday Hong Kong bourse filing said.

The approved indication is for patients with non-small cell lung cancer harboring KRAS G12C mutations who have received at least one prior systemic therapy.

The approval will trigger a 50 million yuan milestone payment to the pharmaceutical company from partner Shanghai Allist Pharmaceuticals (SHA:688578).